• Home
  • Site Map
  • Contact Us
  • Graphics Version
  • Printer Version

Amarin

Main Navigation

  • ABOUT US
    • COMPANY PROFILE
    • STRATEGY
    • EXECUTIVE MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • CONTACT US
  • THERAPEUTIC FOCUS
    • CARDIOVASCULAR
  • PRODUCTS
    • PIPELINE
    • AMR101 for Reducing Cardiovascular Risk
  • SCIENCE & TECHNOLOGY
    • INTRODUCTION
      • Lipophilic Platform
      • Targeted Lipid Transport Technology Platform
      • Cholinergic Platform
  • PARTNERING
    • PARTNERING
  • INVESTOR RELATIONS
    • OVERVIEW
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
      • AUDIT COMMITTEE
      • REMUNERATION COMMITTEE
      • CODE OF ETHICS
      • MEMORANDUM AND ARTICLES OF ASSOCIATION
    • PRESENTATIONS
    • PRESS RELEASES
    • EVENTS
    • INVESTOR FAQ
    • REQUEST INVESTOR KIT
    • FINANCIAL REPORTS
    • SEC FILINGS
    • EGM 2008
    • ANALYST COVERAGE
    • EMAIL ALERTS
    • REQUEST INFORMATION

PRODUCTS

  • PIPELINE
  • AMR101 for Reducing Cardiovascular Risk

Mailing List

Mailing List
Unsubscribe »

Registered in England and Wales No. 2353920 - Registered Office: 110 Cannon Street, London, EC4N 6AR

  • Disclaimer
  • Privacy Policy

© 2010 Amarin

Link opens in new windowWeb Design by Webtrade.ie